Page 6,810«..1020..6,8096,8106,8116,812..6,8206,830..»

Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

Posted: Published on June 5th, 2012

ROCKVILLE, Md., June 5, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the Emory University Institutional Review Board (IRB) approved the amendment to the ongoing Phase I trial evaluating Neuralstem's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The amendment permits the return of three previously-treated patients to the trial to receive additional injections of cells. This modification to the protocol was approved earlier by the Food and Drug Administration (FDA). Implementation was contingent upon IRB approval, which has now been secured. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "Bringing patients back for a second set of injections should they meet the inclusion requirements at the time of surgery, or giving new patients both lumbar and cervical injections, is a major step forward toward testing the maximum safe dosing of our cell therapy," said Richard Garr, Neuralstem President & CEO. "We have been encouraged by the results of the trial to date, and are eager to commence treating patients with this increased dosage." About the Study The ongoing Phase I study is designed to assess the safety of Neuralstem's spinal cord stem cells (HSSC's) and transplantation technique in up to 18 patients with ALS. The … Continue reading →

Comments Off on Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

The potential impact of olfactory stem cells as therapy reported in Cell Transplantation

Posted: Published on June 5th, 2012

Public release date: 5-Jun-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Tampa, Fla. (June 5 , 2012) A study characterizing the multipotency and transplantation value of olfactory stem cells, as well as the ease in obtaining them, has been published in a recent issue of Cell Transplantation (20:11/12), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/. "There is worldwide enthusiasm for cell transplantation therapy to repair failing organs," said study lead author Dr. Andrew Wetzig of the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia. "The olfactory mucosa of a patient's nose can provide cells that are potentially significant candidates for human tissue repair." According to the study authors, olfactory neural stem cells can be derived from a patient's own cells, they are readily available by a minimally invasive biopsy technique, and they can be expanded in vitro. The cells are plentiful because the olfactory epithelium undergoes neurogenesis and continual replacement of sensory neurons throughout adult life. "Using the rat as our animal model source, we examined the basic aspects of olfactory neural stem cell biology and its potential for self-renewal and phenotypic expression in various … Continue reading →

Comments Off on The potential impact of olfactory stem cells as therapy reported in Cell Transplantation

Why David Simon is wrong about paywalls

Posted: Published on June 5th, 2012

Let me count the ways. Ten, in fact. David Simon is a talented writer and storyteller, but is he qualified to give advice to publishers about how to save their dying industry? As qualified as anybody else, I suppose. But when he suggested in a recent piece for CJR that people like me who disagree with his position on paid content were unqualified, that got under my skin a bit. Simon wrote, These folks (paywall opponents) dont understand the first thing about actual journalism. He also lumped us in with an imaginary crowd of people who supposedly think amateurs can replace professionals, though we take no such position. To Simons credit, he engaged readers in comments on his CJR piece, but the conversation turned more into a quibble over the definition of ad hominem than a dialogue about the important issues facing newspapers. I decided to step back and lay out my thoughts in a more organized fashion. First, Simon and I agree: that journalism is important. That newspapers giving their content away for free online is a bad idea. That investigative/enterprise journalism is expensive. That the beat system plays an important role in watchdog journalism, and beat journalism requires … Continue reading →

Posted in Impotency | Comments Off on Why David Simon is wrong about paywalls

Four-Drug Mix Treats Multiple Myeloma With Fewer Side Effects, Mayo Clinic-Led Study Finds

Posted: Published on June 5th, 2012

Monday, June 04, 2012 SCOTTSDALE, Ariz. A four-drug combination of chemotherapy drugs scored high marks as a highly effective treatment for patients newly diagnosed with the blood cancer multiple myeloma, according to results from a Mayo Clinic-led study. The multidrug regimen, called CYCLONE (comprised of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone), boasted strong results in the phase II trial, most notably for how quickly and effectively it worked and how well tolerated it was by the study recipients. VIDEO ALERT: click here for footage of Dr. Mikhael. "Within only four cycles of treatment, 96 percent of patients responded favorably to the therapy," says lead researcher Joseph Mikhael, M.D., a hematologist at Mayo Clinic in Arizona. "Furthermore, 75 percent experienced a very good partial remission meaning there was a 90 percent reduction of their tumor. A third of the patients experienced a complete remission, where the tumor was no longer detectable." Dr. Mikhael is presenting the study at an American Society of Clinical Oncology conference in Chicago. The study participants also experienced fewer side effects compared to currently available therapies, Dr. Mikhael adds. Side effects associated with multiple myeloma treatment typically involve the nerves of the body, and include numbness, tingling and … Continue reading →

Posted in Drug Side Effects | Comments Off on Four-Drug Mix Treats Multiple Myeloma With Fewer Side Effects, Mayo Clinic-Led Study Finds

Weymouth native tackles addiction in new book

Posted: Published on June 5th, 2012

Dan Farish said he has never met anyone who struggled with alcohol or drug dependency who did not have a poor self-esteem or were dealing with physical or emotional abuse. Farish said a dysfunctional home he grew up in on Washington Street in Idlewell during the 1960s and early 1970s helped set the stage for him to abuse alcohol, a struggle he details in 3 Steps To Recovery, a book on sale at local bookstores. My parents never drank at all, said Farish, who now lives in Washington State and works as a substance abuse recovery coach My father had major anger problems and my mother was subservient to him. There was a lot of unhappiness in the house. My father would go to work angry, and hed come home angry. My mother was in denial all the time. Farish said his father would sometimes strike his sister. He was always looking for someone to bully, he said. If he saw kids riding a mini-bike, he would call the police. I caught a lot of flak for that. Both of Farishs parents are deceased, and he said his home life, coupled with some bullying he endured as a middle school … Continue reading →

Posted in Drug Dependency | Comments Off on Weymouth native tackles addiction in new book

PetCareRx Selects Whitegate PR as Agency of Record

Posted: Published on June 5th, 2012

NEW YORK, June 5, 2012 /PRNewswire/ --PetCareRx selects boutique public relations firm Whitegate PR as their agency of record. PetCareRx is America's leading online pet pharmacy. They offer only the highest quality pet medications, food, supplies and accessories and carry all EPA and FDA approved heartworm, flea, tick and chronic illness medications and more. Providing for and taking care of a pet can be very time consuming and costly, especially in today's society. PetCareRx.com helps consumers to save time and money, and ensure that their pets have everything they could possibly need. Whitegate PR is customizing a Public Relations and Marketing plan to increase exposure for http://www.petcarerx.com among pet owners in the United States. PetCareRx was established to give pet owners the products they require, at fair and reasonable prices. PetCareRx isn't a club and doesn't charge a membership fee but is instead a pet pharmacy that is convenient because it is just a click or phone call away. They offer all the brands pet owners trust, at prices that defy the competition. Jen from Dallas, Texas, "I just used PetCareRx for the first time and I will definitely be back. Great product selection, prices and excellent customer service. I … Continue reading →

Posted in Online Pharmacy | Comments Off on PetCareRx Selects Whitegate PR as Agency of Record

Tazewell Police looking for suspects in pharmacy burglaries

Posted: Published on June 5th, 2012

TAZEWELL, Va. -- The Tazewell Police Department is investigating a two pharmacy break-ins today. According to reports from the department, at around 3 a.m. on June 3 the Hayes Pharmacy was broken into by two people one of whom began removing items off the pharmacy shelves. The second suspect allegedly drove the getaway vehicle. On the same day, about an hour and 20 minutes later, the Claypool Hill Pharmacy was broken into as well. Police tell us that they believe the same two suspects in the Hayes Pharmacy break-in were responsible for the Claypool Hill Pharmacy burglary. In both crimes, police say the suspects used a rock to break out a window and entrance was made by one suspect, while the second suspect waited nearby in a vehicle. The suspect that entered the pharmacies is described as 56-57 in height and between 110-130 pounds. Police say theyre reviewing several videos, taken by surrounding video cameras located at banks and traffic lights around the two pharmacies. If anyone have any information regarding these two incidents please contact the Tazewell County Sheriffs office at (276) 988-1161 or the Tazewell Police Department at (276) 988-2503. See the original post: Tazewell Police looking for … Continue reading →

Posted in Pharmacy | Comments Off on Tazewell Police looking for suspects in pharmacy burglaries

Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN® and Belinostat at the 2012 American Society of …

Posted: Published on June 5th, 2012

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced promising clinical data in five poster presentations for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use, as well as a poster presentation and one e-abstract publication for belinostat, at the American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois, from June 1-5, 2012. ZEVALIN Promising clinical findings in DLBCL, including in elderly patients; ZEVALIN further associated with reduced need for chemotherapy A Phase 2 investigator-sponsored study in patients with stage III/IV CD20+ DLBCL (Abstract # 6633) found that short-duration therapy consisting of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (RCHOP-14) followed by ZEVALIN resulted in a 3-year overall survival (OS) of 100%. Three-year progression-free survival (PFS) was 90% in this patient cohort. The Phase 2 study was an international, open-label, non-randomized trial in a total of 30 CD20+ DLBCL patients aged between 65 and 80, 25 of whom completed treatment. An additional investigator-sponsored Phase 2 study (Abstract #8056) demonstrated that short-duration therapy of ZEVALIN with rituximab showed complete response rate durations comparable to full-course R-CHOP in … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN® and Belinostat at the 2012 American Society of …

Bone marrow transplant drug a step closer

Posted: Published on June 5th, 2012

A DRUG that stops the body from rejecting bone marrow transplants in cancer patients could be ready for human trials in three years time. The latest development comes after more than a decade of research unlocking the function of a protein called perforin, which kills rogue cells in the body. Australian researchers involved in unravelling perforin's molecular structure, a discovery published in the journal Nature in 2010, are now working towards developing a safe drug to block the protein. Perforin plays a key role in the body's immune response by punching holes in, and killing, cells which have been hijacked by viruses or cancer to rid the body of disease. However, the protein is problematic for bone marrow transplant patients because it can cause the body to reject the treatment. For this reason, a project led by the Peter MacCallum Cancer Centre in Melbourne is developing a drug to inhibit the protein in bone marrow stem cell transplant patients to help their recovery. The drug works in mouse models, but a $6.8 million grant from the UK's Wellcome Trust will allow the drug to be fine-tuned for human trials. "In the mouse models we use, we know the inhibitors are … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Bone marrow transplant drug a step closer

Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

Posted: Published on June 5th, 2012

ROCKVILLE, Md., June 5, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the Emory University Institutional Review Board (IRB) approved the amendment to the ongoing Phase I trial evaluating Neuralstem's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The amendment permits the return of three previously-treated patients to the trial to receive additional injections of cells. This modification to the protocol was approved earlier by the Food and Drug Administration (FDA). Implementation was contingent upon IRB approval, which has now been secured. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "Bringing patients back for a second set of injections should they meet the inclusion requirements at the time of surgery, or giving new patients both lumbar and cervical injections, is a major step forward toward testing the maximum safe dosing of our cell therapy," said Richard Garr, Neuralstem President & CEO. "We have been encouraged by the results of the trial to date, and are eager to commence treating patients with this increased dosage." About the Study The ongoing Phase I study is designed to assess the safety of Neuralstem's spinal cord stem cells (HSSC's) and transplantation technique in up to 18 patients with ALS. The … Continue reading →

Comments Off on Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

Page 6,810«..1020..6,8096,8106,8116,812..6,8206,830..»